(NASDAQ: MEDS) Datameds Ai's forecast annual revenue growth rate of 20.89% is not forecast to beat the US Pharmaceutical Retailers industry's average forecast revenue growth rate of 134.3%, and while it is forecast to beat the US market's average forecast revenue growth rate of 16.27%.
Datameds Ai's revenue in 2026 is $14,033,980.On average, 3 Wall Street analysts forecast MEDS's revenue for 2026 to be $13,132,646, with the lowest MEDS revenue forecast at $12,619,907, and the highest MEDS revenue forecast at $13,519,713. On average, 3 Wall Street analysts forecast MEDS's revenue for 2027 to be $44,138,256, with the lowest MEDS revenue forecast at $42,409,020, and the highest MEDS revenue forecast at $45,437,697.
In 2028, MEDS is forecast to generate $97,370,085 in revenue, with the lowest revenue forecast at $93,549,679 and the highest revenue forecast at $100,232,876.